Меню
Идёт набор NCT05324475

Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition.

Без фазы С лечением Malnutrition Sarcopenia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: BCAA, Micronutriments, standard treatment + placebo.
Кому может быть актуально
Состояния в реестре: Malnutrition, Sarcopenia. Базовые параметры: от 75 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Швейцария
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition: the MIMOSA Study.

Обзор

Aging is associated with an increased inflammation named "inflammageing" and with an altered immune response. Different mechanisms have been proposed to explain the phenomenon of inflammageing and increased oxidative stress: deficiencies in essential amino acids, and some micronutrients have an important impact and may induce immune cell dysregulation. Mitochondrial dysfunction may explain the complex relationship between malnutrition sarcopenia, immune dysfunction and aging. Therefore, a personalized nutritional strategy aiming to improve mitochondrial function, decrease oxidative stress, down-regulate inflammation and restore immunity appears to be a logical approach in order to treat malnutrition and its biological and clinical consequences. MIMOSA will investigate the role of nutritional supplements in rescuing altered mitochondrial function and redox state imbalance.

Подробное описание

The study participants will all receive optimal standard care ensuring the optimal protein and energy intakes, with at least 1 g protein per kg body weight and day, and 30 kcal per kg body weight and day (or the measured energy expenditure (EE) value). This will be realized by the daily administration of oral nutritional supplements (ONS) providing whole proteins together with dietary advice \[according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, Nestlé) and nutritional counselling (SC).

All participants included in this study will receive daily, the oral nutritional supplement (ONS), one sachet and two capsule (for blinding purpose).

The intervention nutrients will be delivered as follows:

* BCAA: 1 sachet containing 4 g of BCAA (details in Table 1) * Micronutrients: 1 sachet containing 4 g of the micronutrient blend and 2 capsules containing 0.6 g of OMEGA 3 PUFA (details in table 1).

The placebos will be delivered like this:

-1 sachet containing 1 g of maltodextrin and 2 capsules containing 0.6 g of coconut oil. (detailed in Table 1).

The duration of the intervention will be 6 weeks, but at least 4 weeks After enrollment patients will be subjected to evaluation of muscle mass by bioimpedance (BIA), muscle strength will be by handgrip strength and muscle performance by the Short Performance Physical Battery (SPPB).

Nutritional status will be evaluated by the Mini Nutritional Assessment short form (MNA-SF), Nutrition Risk screening (NRS) score and Body mass index (BMI). Energy expenditure (EE) will be measured by indirect calorimetry using a canopy.

Moreover appropriate experiments will be carried out in order to evaluate mitochondrial bioenergetics, replication, and fusion, as well as of redox state.

Analyses of inflammageing and immune-senescence will be done by appropriate lab experiments.

Micronutrient status will be measured by ELISA or HPLC and ICPMS respectively. Patients will be evaluated at inclusion, at rehabilitation discharge, and one and two months after rehabilitation discharge. The volume of blood required for the above investigations will be 3 x 30 ml over the 2-month period.

Вмешательства

  • Пищевая добавка BCAA
    daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
  • Пищевая добавка Micronutriments
    daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
  • Пищевая добавка standard treatment + placebo
    daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo

Первичные конечные точки

  • Change in mitochondrial ATP production (nmol/ml) [Срок оценки: change vesus baseline at 30, 60 days after discharge]
  • Change in redox state (plasmatic concentration of metabolites) [Срок оценки: change vesus baseline at 30, 60 days after discharge]
  • Change in mitochondrial electron flux (nmol cit/min/mg prot) [Срок оценки: change vesus baseline at 30, 60 days after discharge]
Вторичные конечные точки (7)
  • change micronutrients status (concentration of micronutrients) [Срок оценки: change versus baseline at 60 days after discharge]
  • change in inflammation [Срок оценки: change versus baseline at 30, 60 days after discharge]
  • change phase angle (score) [Срок оценки: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge]
  • muscle function (score) [Срок оценки: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge]
  • muscle mass (Kg/body weight) [Срок оценки: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge]
  • muscle strength (Kg) [Срок оценки: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge]
  • change in perceived health status (score) [Срок оценки: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge]

Критерии участия

Критерии включения

  • Age ≥75 years
  • Patients entering a rehabilitation program
  • Diagnosis of malnutrition defined by a MNA-SF (mini-nutritional assessment short form) score below 11 points.
  • Commitment to accept the nutritional supplement proposed, willing and able to give written informed consent
  • Ability to understand and comply with the requirements of the study

Критерии исключения

  • Presence of malignancy,
  • Life expectancy of less than two months calculated by Multidimensional Prognostic Index (MPI ),
  • Congestive heart failure (NYHA IV),
  • Chronic renal disease (creatinine clearance <40 ml/min calculated by cockroft),
  • Liver cirrhosis (Child B-C),
  • Tube/percutaneous endoscopic gastrostomy feeding or parenteral nutrition,
  • Severe dysphagia,
  • Mini-Mental State Examination (MMSE)≤18 and MNA>11 points. MMSE ≥ 18 identifies patients with mild form of cognitive impairment; those patients generally do not have problems in swallowing and are able to take drugs.
  • Severe anaemia (Hb<10 g/l) or leukopenia (<2G/l).

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Швейцария · 1 центр
  • CHUV — Lausanne

Идентификаторы

NCT: NCT05324475 · MIMOSA

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗